Sirolimus experience in heart transplantation.

Area of Science:

• Nephrology
• Immunology
• Cardiology

Background:

• Sirolimus is an immunosuppressant with antiproliferative properties.
• It is nonnephrotoxic and shows potential for managing renal dysfunction post-transplant.
• Limited data exist on de novo sirolimus regimens in high-risk patients.

Purpose of the Study:

• To evaluate sirolimus-based immunosuppression in heart transplant recipients.
• To assess sirolimus for converting from calcineurin inhibitors (CNIs) in patients with renal dysfunction.
• To evaluate de novo sirolimus regimens in select heart transplant patients.

Main Methods:

• Retrospective analysis of 25 heart transplant recipients.
• 17 patients converted from CNIs to sirolimus for renal dysfunction.
• 6 patients received a de novo sirolimus regimen; 2 received it due to posttransplant neoplasms.

Main Results:

• Serum creatinine levels significantly decreased post-conversion from CNIs to sirolimus.
• Kidney function improved and was maintained up to 1 year post-conversion.
• The de novo sirolimus group showed a higher incidence of moderate rejection; side effects were common.

Conclusions:

• Sirolimus effectively improved late CNI-related chronic renal dysfunction in heart transplant recipients.
• A de novo CNI-free regimen with sirolimus preserved kidney function in recent heart transplant recipients.
• Sirolimus use requires careful monitoring due to potential side effects and rejection rates.